drugset / Trial / NCT04585893
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
Phase 2
Active not recruiting
15 enrolled
UNC Lineberger Comprehensive Cancer Center
Fogarty International Center of the National Institute of Health · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness of first-line Rituximab treatment for MCD in Malawi to chemotherapy.
Timeline
- Start
- 2021-06-22
- Primary completion
- 2024-08-30
- Completion
- 2026-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |